Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ritanserin in Treatment of Cocaine Dependence - 1

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000187
First received: September 20, 1999
Last updated: May 26, 2015
Last verified: May 2015
  Purpose
The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Ritanserin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Ritanserin in Treatment of Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Cocaine use
  • Cocaine craving

Enrollment: 80
Study Start Date: July 1992
Primary Completion Date: June 1994 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   28 Years to 47 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000187

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: James Cornish, M.D. University of Pennsylvania
  More Information

Publications:
Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000187     History of Changes
Other Study ID Numbers: NIDA-00144-1  3R01DA012268  K20-00144-1 
Study First Received: September 20, 1999
Last Updated: May 26, 2015
Health Authority: United States: Federal Government

Keywords provided by University of Pennsylvania:
Cocaine Dependence
ritanserin

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Ritanserin
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Serotonin Antagonists
Serotonin Agents
Antipsychotic Agents
Tranquilizing Agents
Psychotropic Drugs
Anti-Anxiety Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents

ClinicalTrials.gov processed this record on December 02, 2016